Panblok

BIOLOGICAL2 trials

Sponsors

Protein Sciences Corporation

Conditions

Influenza

Phase 1

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

CompletedNCT01612000

Protein Sciences CorporationInfluenza

Start: 2012-05-31End: 2013-12-31Updated: 2015-11-25

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

CompletedNCT02464163

Protein Sciences CorporationInfluenza

Start: 2015-07-31End: 2016-08-31Updated: 2017-10-26

Related Papers

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.

2017-01-1110 citations